Department of Orthopaedics, The 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Department of Orthopaedics, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Int J Nanomedicine. 2018 Jan 31;13:617-631. doi: 10.2147/IJN.S142797. eCollection 2018.
Cartilage degeneration affects millions of people but preventing its degeneration is a big challenge. Although RNA interference (RNAi) has been used in human trials via silencing specific genes, the cartilage RNAi has not been possible to date because the cartilage is an avascular and very dense tissue with very low permeability.
The objective of this study was to develop and validate a novel lipid nanoparticle (LNP)-siRNA delivery system that can prevent cartilage degeneration by knocking down specific genes.
LNP transfection efficiency was evaluated in vitro and ex vivo. Indian Hedgehog () has been correlated with cartilage degeneration. The in vivo effects of LNP-Ihh siRNA complexes on cartilage degeneration were evaluated in a rat model of surgery-induced osteoarthritis (OA).
In vitro, 100% of chondrocytes were transfected with siRNA in the LNP-siRNA group. In accordance with the cell culture results, red positive signals could be detected even in the deep layer of cartilage tissue cultures treated by LNP-beacon. In vivo data showed that LNP is specific for cartilage, since positive signals were detected by fluorescence molecular tomography and confocal microscopy in joint cartilage injected with LNP-beacon, but not on the surface of the synovium. In the rat model of OA, intraarticular injection of LNP-Ihh siRNA attenuated OA progression, and PCR results showed LNP-Ihh siRNA exerted a positive impact on anabolic metabolism and negative impact on catabolic metabolism.
This study demonstrates that our LNP-RNAi delivery system has a significantly chondroprotective effect that attenuates cartilage degeneration and holds great promise as a powerful tool for treatment of cartilage diseases by knocking down specific genes.
软骨退变影响着数以百万计的人,但预防其退变是一个巨大的挑战。尽管 RNA 干扰(RNAi)已通过沉默特定基因在人体试验中得到应用,但迄今为止,软骨 RNAi 还无法实现,因为软骨是一种无血管且非常致密的组织,通透性非常低。
本研究旨在开发和验证一种新型脂质纳米颗粒(LNP)-siRNA 递药系统,通过敲低特定基因来预防软骨退变。
体外和离体评估 LNP 转染效率。Indian Hedgehog()与软骨退变相关。通过手术诱导的骨关节炎(OA)大鼠模型评估 LNP-Ihh siRNA 复合物对软骨退变的体内作用。
在体外,LNP-siRNA 组 100%的软骨细胞转染了 siRNA。与细胞培养结果一致,即使在用 LNP-beacon 处理的软骨组织培养物的深层也可以检测到红色阳性信号。体内数据表明 LNP 对软骨具有特异性,因为在用 LNP-beacon 注射的关节软骨中可以通过荧光分子断层扫描和共聚焦显微镜检测到阳性信号,但在滑膜表面则没有。在 OA 大鼠模型中,关节内注射 LNP-Ihh siRNA 可减轻 OA 进展,PCR 结果表明 LNP-Ihh siRNA 对合成代谢有积极影响,对分解代谢有消极影响。
本研究表明,我们的 LNP-RNAi 递药系统具有显著的软骨保护作用,可减轻软骨退变,有望成为通过敲低特定基因治疗软骨疾病的有力工具。